Lexaria has patented and commercialized the world’s newest all-new drug delivery technology (DehydraTECH™) that has been both laboratory and market proven to enhance the performance of several categories of drugs, always in oral and/or topical product formats:
Lexaria’s technology is easily applied through incorporation of an intermediate step in the formulation and manufacturing of existing or new orally-ingestible and topical products. This step involves mixing the beneficial compound of interest as a delivery “payload” together with certain fatty acids, infusing the mixture into a substrate material, and then using controlled dehydration synthesis processing to conjugate the payload and fatty acids together at a molecular level before integrating the newly-combined molecules into production.
Click image to view our DehyraTECH Information Sheet to learn more:
Click on the video above to view a video explaining Lexaria’s DehydraTECH™ technology and illustrating how it is used to formulate and manufacture high performance ingestible consumer products.
Compounds processed using Lexaria’s DehydraTECH™ system become masked to oral and olfactory receptors, rendering them essentially flavorless and odorless. As such, DehydraTECH™ formulations do not require unwanted sweeteners or chemical masking agents for flavor and odor blocking. This allows manufacturers to create low-sugar products with fewer calories, while also avoiding the use of excessive artificial sweeteners.
After being swallowed, the fatty acids are believed to protect the conjugated payload from hostile stomach conditions and expedite its transit to the small intestine where nutrient bioabsorption occurs. Once in the small intestine, the fatty acids are believed to enable rapid and more significant permeation of the intestinal wall for the conjugated payload, then transport it to the systemic circulation by one of two pathways depending on the type of fatty acid(s) chosen for each specific formulation:
In cases where liver metabolism is desirable for biotransformation of the payload before access to the general circulation, Lexaria’s methodology uses medium chain fatty acids for formulation purposes since they are absorbed via the portal vein and transported to the liver for processing prior to entering the general circulation. This would be applicable, for instance, with prodrug compounds that rely on metabolism by liver enzymes to become pharmacologically active within the human body.
Conversely, in cases where faster onset of action and/or maximizing action of the originally formulated payload without biotransformation is desirable, Lexaria’s methodology uses long chain fatty acids, which are absorbed via the lymphatic lacteals thereby diverting away from the liver and entering the general circulation very quickly. For payloads that deliver pain relief or meet other immediate needs, this rapidity of onset is a vital benefit.
For Non Steroidal Anti-Inflammatory Drugs (“NSAIDs”) such as Ibuprofen and similar, this is a crucial distinction in offering protection to the kidneys from known harmful effects otherwise associated with first-pass liver metabolism of those NSAID products.
DehydraTECH™ formulations may also permit formulation with a combination of long and medium chain fatty acids in the same preparation for purposes of engineering products with both fast and sustained release profiles. Such timed-release formulations can be sought to deliver beneficial payloads both quickly, as well as over a sustained duration for several hours.
DehydraTECH™ formulations have been shown through in vitro and in vivo studies to increase intestinal bioabsorption of bioactive compounds by as much as 5-10X and demonstrate effectiveness in as little as 15 minutes after administration (see: Research).
Lexaria’s DehydraTECH™ process has the added benefit of being very cost-effective to implement; requiring micro quantities of fatty acid ingredient incorporation into drugs, consumer packaged goods (“CPG”) , and capsule products at a fraction of a penny per serving, together with the use of processing equipment that is readily found in most commercial kitchen/production facilities and is highly scalable.
Lexaria’s DehydraTECH™ is designed specifically for formulating and delivering lipophilic (i.e. fat-soluble) payloads. DehydraTECH is protected by a robust suite of patents-pending or patents granted around the world covering its use with a broad range of bioactive molecules, including Nicotine, common NSAID pain-relievers, and much more.
Lexaria’s technology is best thought of as an additional layer that companies offering consumer supplements, prescription and non-prescription based drugs, and nicotine products can utilize to improve the effectiveness of their existing or planned new products. Lexaria Bioscience Corp. has no plans to create and sell Lexaria-branded products containing controlled substances. Instead, Lexaria licenses its advanced technology to other companies around the world to offer consumers the best performance possible across an array of product formats.
Lexaria Bioscience Corp. (“Lexaria”) has formed the Lexaria Nicotine Corp. as its exclusive worldwide nicotine business unit. More than 89% of all nicotine that is consumed worldwide is delivered through smoking cigarettes, causing over 6,000,000 deaths per year around the world according to the Centers for Disease Control and Prevention. Of note: “…it is primarily the toxins and carcinogens in tobacco smoke – not the nicotine – that cause illness and death.” (U.K. National Institute for Health and Care Excellence [NICE]). As many as 69% of U.S. adult smokers want to quit smoking and 43% of US adult smokers have attempted to quit in any twelve-month period. Lexaria postulates that delivery of nicotine to satisfy current demand, utilizing our patented DehydraTECH technology in common oral and consumer product formats, could shift demand away from smoking cigarettes. However, oral forms of nicotine are challenging because it is poorly tolerated by the human gastrointestinal system and then significantly metabolized by the liver, thereby diminishing its overall effectiveness. Lexaria’s DehydraTECH technology offers a means to formulate oral product formats of nicotine and/or its analogs with higher bioavailability performance possibilities due to the benefits of our technology. DehydraTECH has been investigated thoroughly related to nicotine oral delivery.
Lexaria is developing a patent suite with supporting intellectual property in the pharmaceutical sector that will supply significant long-term strategic growth potential. Lexaria Pharmaceutical Corp. is the 100%-owned subsidiary that has obtained exclusive worldwide rights to Lexaria’s patent portfolio related to pharmaceutical applications. Currently within this business unit resides the IP for Non-Steroidal Anti-Inflammatories (NSAIDs), Vitamins, hormone treatments utilizing estrogen or testosterone and phosphodiesterase inhibitors (PDE5). Most recently, Lexaria’s technology is being examined for the delivery of antiretroviral drugs with potential applications against Coronavirus.
According to Statista.com, the global pharma industry was worth $1,105 billion in 2016, and the US pharma industry alone spent over $71 billion in 2017 on R&D: a larger R&D expenditure than the entire gross revenues of many other business sectors.. Lexaria Pharmaceutical Corp. is implementing a strategy of reinforcing its IP-suite to sufficient degree to begin partnering within this dynamic industry.
The Lexaria Hemp Co. holds exclusive global rights to the Lexaria patent portfolio related to hemp-based applications. Lexaria’s DehydraTECH technology is designed to deliver functional ingredients within hemp in oral product formats with significantly enhanced palatability, speed of effectiveness and potency as a viable and healthier alternative to conventional inhalational (i.e. smoking or vaping) administration practices. Extensively evaluated through invivo, invitro, and human clinical studies, one of the most extensive databases in the world has been collected by Lexaria related to hemp-based ingredients empowered with our DehydraTECH technology. In 2018, the World Anti Doping Agency (WADA) for the first time ever exempted cannabidiol from hemp from its list of restricted substances on its International Standards Prohibited List of substances.
Lexaria CanPharm Corp, a Canadian corporation, owns exclusive global rights to Lexaria’s intellectual property as it is applied to psychotropic bioactive molecules that act upon human CB1 and CB2 receptors in those areas of the world where it is permissible to do so. Substances that act upon these receptors and systems in the human body that affect pain, inflammation, anxiety and depression, and have also been shown to have utility against cancer and neurodegenerative conditions. Lexaria’s ground-breaking 2018 research that proved many-fold improvements in delivering an active ingredient across the blood-brain-barrier could have disruptive potential within this business sector as well as all others where Lexaria is active.
Lexaria’s methodology can be applied to many different ingestible product formats including foods, beverages, oral suspensions, tablets, capsules and more. This is accomplished through choosing an appropriate substrate compound for infusion during performance of the Lexaria formulation and manufacturing process, which can range from a foodstuff like cocoa powder or tapioca starch used in many confectionary products, or an emulsifier like gum arabic used in many beverage products. Many of the most common base ingredients used in modern processing of foods, beverages and supplements are effective to use with DehydraTECH™.
The safety and effectiveness of Lexaria’s DehydraTECH technology has been studied in a series of controlled and well designed in vitro, in vivo studies, examining factors such as total bioabsorption directly and indirectly through surrogate biomarkers, time to onset of effectiveness, flavor appeal and quality of effectiveness. In 2018 Lexaria completed one of the world’s first human clinical, double-blinded, placebo-controlled investigations into hemp extracts treated with DehydraTECH processes. Studies also include two 2018 animal studies that delivered ground breaking results showcasing the improvements of nicotine delivery both to blood plasma as well as across the blood-brain-barrier.
Lexaria’s DehydraTECH technology is covered by a robust suite of issued and pending patents in over 40 countries around the world. Lexaria`s patent suite commenced with two initial 2014 US provisional patent applications. Since then, Lexaria has broadened the patent suite considerably by refining the patent claims via further US provisional and utility patent filings, extending the breadth of the claims considerably to name other compounds including but not limited to vitamins and NSAIDs, that the technology can be applied to and many other consumer product formats in which they can be formulated. Under US patent law, a patent upon issuance provides for 20 years of patent protection from the date of filing.
In addition to the US patent filings, Lexaria has also pursued international patent protection through filings under the Patent Cooperation Treaty, followed by national filings in 40+ jurisdictions of highest commercial potential thereunder. Links to our very first US and Australian patents are provided for your convenience, below.